London, UK-based femtech company Flo Health has announced a multi-year strategic partnership with Google Health to integrate menstrual health tracking with wearable data and personalized health coaching.
Google Health has also made a strategic investment in Flo, although the companies have not disclosed the amount or financial terms.
The partnership will connect Flo’s menstrual and reproductive health tracking platform with Google’s wearable technology and Google Health Coach. The integration is scheduled to begin in early 2027.
Connecting Menstrual Health Data With Wearable Tracking
Founded in 2015, Flo Health develops a digital platform for menstrual cycle tracking, ovulation predictions, pregnancy monitoring and reproductive health information.
The company reports more than 80 million monthly active users worldwide and over 500 million cumulative downloads since its launch.
Under the partnership, users who choose to connect Flo with Google Health will be able to combine menstrual cycle information with Fitbit wearable data, including sleep patterns, heart rate, heart rate variability, skin temperature and respiratory rate.
These signals are intended to improve cycle predictions and provide more personalized insights into symptoms and different reproductive life stages.
Flo’s health insights will also be available within Google Health, allowing its coaching features to account for menstrual cycle phases and other relevant information.
Flo will become Google Health’s featured women’s health partner within the Google Health app.
The companies say data sharing will require explicit user consent for each data category and purpose. Users will be able to withdraw permission, and Flo data shared with Google Health will not be used for advertising, sold or made available to third-party developers through Google’s health platforms.
Developing AI Research and New Women’s Health Products
Beyond the initial software integration, Flo Health and Google Health plan to develop co-branded products combining Flo’s reproductive health algorithms with Google’s wearable hardware and sensor technology.
The companies will also establish a joint research programme focused on how hormonal changes affect physiological signals and health outcomes.
Research priorities include developing AI models capable of identifying potential early signs of perimenopause and symptom patterns associated with conditions such as polycystic ovary syndrome (PCOS), endometriosis and uterine fibroids.
These capabilities remain research objectives rather than commercially available diagnostic features.
The partnership will also explore how wearable signals could support fertility-related applications, subject to clinical validation and regulatory review.
“Women have waited too long for technology that understands their bodies as well as it understands their steps. A.I. is about to change what is possible in women’s health - but only if it’s built with women in mind, not adapted for them afterward,” said Dmitry Gurski, co-founder and CEO of Flo Health. “Flo has spent more than a decade earning the trust of millions of women who rely on us to learn more about what their cycles and life stages really look like.
Together with Google Health, we’re building on that trust through a privacy-first approach to give every woman insight that is personal, continuous and grounded in science, from her first period to menopause.”
According to the companies, the research will use privacy-preserving methods, including aggregated, pseudonymised and synthetic data, alongside clinical evaluation.
Flo Health became a femtech unicorn in 2024 following an investment from General Atlantic. The company will remain independent under the new partnership.